Porownywarka

VIP vs LL-37 side-by-side

Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.

Wybrane (2/4)

VIPLL-37

Udostępnij porównanie peptydów

Wlasciwosc	VIP	LL-37
Kategoria	Odporność	Odporność
Znany tez jako	Vasoactive Intestinal Peptide, Aviptadil	Cathelicidin, CAP18
Zatwierdzony przez FDA	Nie	Nie
Status kliniczny	Clinical Trials - Multiple indications Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA	Investigational; source notes clinical trials for wound healing and FDA Category 2 restricted status due to limited safety data and immunogenicity concerns. Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA
Czego oczekiwac	Autoimmune conditions, CIRS/mold illness, inflammation	Antimicrobial, infections, biofilm disruption, wound healing
Jak dziala	VIP is reported to act through VPAC1 and VPAC2 receptors. The supplied mechanism evidence links receptor activation to increased cyclic AMP, relaxation of smooth muscle, dilation in vascular and airway tissues, and dampening of inflammatory pathways. The same evidence connects immune effects with reduced NF-kB activity and lower TNF-alpha signaling. Because VPAC receptors are distributed across immune cells, the gut, blood vessels, and the brain, the source characterizes VIP as a broad signaling hormone rather than a narrowly targeted agent.	LL-37 is described as a positively charged, amphipathic host-defense peptide that can associate with negatively charged microbial membranes and disrupt them. Beyond direct antimicrobial effects, the source reports signaling roles that include neutralizing bacterial LPS, shaping inflammatory activity, recruiting immune cells to sites of injury or infection, and supporting epithelial repair. The source notes production in epithelial tissues such as skin, gut, and lung, as well as immune cells including neutrophils.
Typowe dawkowanie	50-100 mcg intranasal daily · 1-2x daily, intranasal · intranasal	100-200 mcg daily · Once daily
Dawkowanie z badań	50-100 mcg IV for acute conditions · Variable by indication · IV infusion, inhaled, or intranasal	100-200 mcg subcutaneous · Variable by protocol · Subcutaneous injection or topical
Typowy czas trwania	Variable by indication	Variable by protocol
Podanie	IV infusion, inhaled, or intranasal	Subcutaneous injection or topical
Timing	Morning or as directed With or without food	Morning With or without food
Poziom dowodów	Badania kliniczne	Badania kliniczne
Mozliwe skutki uboczne	Nausea and diarrhea Injection site reactions Headache +4 więcej Dizziness Facial flushing Blood pressure decrease Short-lived effects due to instability	Injection-site reactions (Reported as common in the source.) Skin toxicity (Source examples include ulcers and burning.) Allergic reactions (Reported by the source without severity grading.) +4 więcej Histamine release (Source flags caution for MCAS or histamine sensitivity.) Possible contribution to autoimmune conditions (Reported as a potential concern, not established causality.) High-dose toxicity concerns (Source flags concern at higher doses.) Limited long-term safety data (Source notes uncertainty around longer-term safety.)
Podsumowanie researchu	The source describes most human evidence for VIP as coming from aviptadil, a synthetic analog. It cites a randomized trial in about 196 critically ill COVID-19 patients with respiratory failure, published in Critical Care Medicine in 2022, where intravenous aviptadil did not meet the 60-day primary endpoint of survival without respiratory failure, although exploratory findings were noted. It also reports that larger and inhaled approaches were evaluated in the ACTIV-3b/TESICO program, with mixed overall results. Outside pulmonary disease, the source mentions rheumatoid arthritis, pulmonary arterial hypertension, and other inflammatory conditions as areas of mechanistic or early-stage study. The supplied evidence explicitly does not support anti-aging, longevity, or general wellness claims.	The source presents LL-37 as a well-studied endogenous component of human innate immunity, with literature support for broad antimicrobial activity, membrane disruption, and distribution across epithelial and immune tissues. It also reports exploratory research on LL-37 or related mimics in laboratory anticancer models, Helicobacter pylori host-defense research, and ocular-surface pathogen contexts. The evidence described is strongest for LL-37 as a natural immune peptide; deliberate administration remains experimental in the supplied source, and the source flags that LL-37 may worsen inflammation in some disease settings.
Referencje	Źródło Źródło +2 więcej Źródło Źródło	Peptibase peptides Peptibase peptides +3 więcej Peptibase peptides Peptibase peptides Peptibase peptides
Pełny profil	Zobacz szczegóły	Zobacz szczegóły

Zapisz to porównanie

Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.

Zapisz porównanie - darmowe konto

Trackuj swoja ścieżkę peptydówa

Zamien research w prywatny log protokołu, gdy będziesz gotowy.

Trackuj ścieżkę peptydówa

Wyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.

Wlasciwosc

VIP

LL-37

Kategoria

Odporność

Znany tez jako

Vasoactive Intestinal Peptide, Aviptadil

Cathelicidin, CAP18

Zatwierdzony przez FDA

Nie

Status kliniczny

Clinical Trials - Multiple indications

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Investigational; source notes clinical trials for wound healing and FDA Category 2 restricted status due to limited safety data and immunogenicity concerns.

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Czego oczekiwac

Autoimmune conditions, CIRS/mold illness, inflammation

Antimicrobial, infections, biofilm disruption, wound healing

Jak dziala

VIP is reported to act through VPAC1 and VPAC2 receptors. The supplied mechanism evidence links receptor activation to increased cyclic AMP, relaxation of smooth muscle, dilation in vascular and airway tissues, and dampening of inflammatory pathways. The same evidence connects immune effects with reduced NF-kB activity and lower TNF-alpha signaling. Because VPAC receptors are distributed across immune cells, the gut, blood vessels, and the brain, the source characterizes VIP as a broad signaling hormone rather than a narrowly targeted agent.

LL-37 is described as a positively charged, amphipathic host-defense peptide that can associate with negatively charged microbial membranes and disrupt them. Beyond direct antimicrobial effects, the source reports signaling roles that include neutralizing bacterial LPS, shaping inflammatory activity, recruiting immune cells to sites of injury or infection, and supporting epithelial repair. The source notes production in epithelial tissues such as skin, gut, and lung, as well as immune cells including neutrophils.

Typowe dawkowanie

50-100 mcg intranasal daily · 1-2x daily, intranasal · intranasal

100-200 mcg daily · Once daily

Dawkowanie z badań

50-100 mcg IV for acute conditions · Variable by indication · IV infusion, inhaled, or intranasal

100-200 mcg subcutaneous · Variable by protocol · Subcutaneous injection or topical

Typowy czas trwania

Variable by indication

Variable by protocol

Podanie

IV infusion, inhaled, or intranasal

Subcutaneous injection or topical

Timing

Morning or as directed

With or without food

Morning

With or without food

Poziom dowodów

Badania kliniczne

Mozliwe skutki uboczne

Nausea and diarrhea
Injection site reactions
Headache

+4 więcej

Dizziness
Facial flushing
Blood pressure decrease
Short-lived effects due to instability

Injection-site reactions (Reported as common in the source.)
Skin toxicity (Source examples include ulcers and burning.)
Allergic reactions (Reported by the source without severity grading.)

+4 więcej

Histamine release (Source flags caution for MCAS or histamine sensitivity.)
Possible contribution to autoimmune conditions (Reported as a potential concern, not established causality.)
High-dose toxicity concerns (Source flags concern at higher doses.)
Limited long-term safety data (Source notes uncertainty around longer-term safety.)

Podsumowanie researchu

The source describes most human evidence for VIP as coming from aviptadil, a synthetic analog. It cites a randomized trial in about 196 critically ill COVID-19 patients with respiratory failure, published in Critical Care Medicine in 2022, where intravenous aviptadil did not meet the 60-day primary endpoint of survival without respiratory failure, although exploratory findings were noted. It also reports that larger and inhaled approaches were evaluated in the ACTIV-3b/TESICO program, with mixed overall results. Outside pulmonary disease, the source mentions rheumatoid arthritis, pulmonary arterial hypertension, and other inflammatory conditions as areas of mechanistic or early-stage study. The supplied evidence explicitly does not support anti-aging, longevity, or general wellness claims.

The source presents LL-37 as a well-studied endogenous component of human innate immunity, with literature support for broad antimicrobial activity, membrane disruption, and distribution across epithelial and immune tissues. It also reports exploratory research on LL-37 or related mimics in laboratory anticancer models, Helicobacter pylori host-defense research, and ocular-surface pathogen contexts. The evidence described is strongest for LL-37 as a natural immune peptide; deliberate administration remains experimental in the supplied source, and the source flags that LL-37 may worsen inflammation in some disease settings.

Referencje

Źródło Źródło

+2 więcej

Źródło Źródło

Peptibase peptides Peptibase peptides

+3 więcej

Peptibase peptides Peptibase peptides Peptibase peptides

Pełny profil

Zobacz szczegóły